LIVESTRONG® Foundation CEO TALKS ABOUT MELANOMA FOR MELANOMA AWARENESS MONTH

Story Summary

THIS REPORT BROUGHT TO YOU BY PROVECTUS PHARMACEUTICALS.

MELANOMA RATES ARE RISING.

DOUG ULMAN IS A TWO-TIME MELANOMA SURVIVOR AND CEO OF THE LIVESTRONG FOUNDATION. HE RECENTLY JOINED THE ADVISORY BOARD OF PROVECTUS PHARMACEUTICALS, A COMPANY COMMITTED TO BATTLING MELANOMA THROUGH ITS DEVELOPMENT OF PV-10.

"As a two-time survivor of melanoma, I take extra precautions to prevent another skin cancer diagnosis by wearing protective clothing, sunscreen and making regular visits to my doctor. I also educate myself about the treatment options available and am glad to see industry leaders taking action to fill the need for treatment of late stage melanoma with new breakthrough therapies."

PV-10 IS AN INJECTABLE FORMULATION OF ROSE BENGAL. STUDIES HAVE CONFIRMED THAT PV-10 IMMUNO-CHEMOABLATION OF MELANOMA LESIONS LEADS TO SYSTEMIC ANTI-TUMOR IMMUNITY. PROVECTUS IS SEEKING CONSENSUS ON A PHASE 3 STUDY DESIGN WHICH WILL QUALIFY FOR SPECIAL PROTOCOL ASSESSMENT FOR PV-10 AND SUPPORT FDA APPROVAL, AND IS CONSIDERING THE NEW BREAKTHROUGH THERAPY DESIGNATION FOR PV-10.

FOR MORE VISIT WWW.PVCT.COM.